UNSPSC 51262104: Atiprosin maleate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C20H29N3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50SZ4782J0, chemically known as pyrazino(2,3:3,4)pyrido(1,2-a)indole, 1-ethyl-1,2,3,4,4a,5,6,12b-octahydro-12-methyl-4-(1-methylethyl)-, trans- but more generally known as atiprosin maleate, which bears US NIH Compound Identifier 3034029. Most nations, for tariff and trade purposes, schedule atiprosin maleate under HS 29335995 and SITC 51576.

As of Q4 2014, ATIPROSIN MALEATE remains US FDA's Preferred Term for this commodity. Atiprosin maleate bears US NLM identifiers UMLS ID C0104775 and NCI Concept Code C87434. SMILES: CCN1CCN([C@H]2[C@H]1C3C(C4CCCCC4N3CC2)C)C(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51262104 Atiprosin maleate is a Commodity code that covers pharmaceutical products, though recent state and local activity shows a significant mismatch between the code's nominal scope and what is actually being solicited. The code appears in opportunities seeking naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription program capabilities — none of which align with atiprosin maleate, an antipsychotic medication. State and local health departments and pharmacy benefit programs are the primary issuing bodies, but the opportunities tagged to this code do not reflect purchases of atiprosin maleate itself. The mismatch suggests either miscoding by the procuring agencies or that the code is being applied as a catch-all for pharmaceutical procurement rather than as a specific drug product line.

Recent activity is limited to two opportunities: Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; and the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. Activity is concentrated in Florida and Texas, with no other jurisdictions represented in recent postings. The Seminole County opportunity is a standard IFB with fixed-fee pricing, E-Verify requirements, and FEMA compliance obligations, while the Texas RFI is exploratory market research preceding a formal RFP. The code shows little actionable procurement signal for atiprosin maleate specifically, and pursuing opportunities requires careful verification that the work actually matches your product or service line rather than relying on the code assignment alone.